L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Finerenone in Mild to Severe Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis in Patients with Heart Failure
Gerasimos Filippatos,Rajiv Agarwal,Stefan D. Anker,Peter Rossing,Amer Joseph,Peter Kolkhof,Marc Lambelet,Marco Antonio Lavagnino Viaud,Luis M. Ruilope,George L. Bakris,Bertram Pitt +10 more
TL;DR: In this article , the effects of finerenone in patients with and without a history of heart failure at baseline were analyzed in the FIDELITY substudy, where patients with CKD and type 2 diabetes (T2D) were randomized to either fine-renone or placebo.
Journal ArticleDOI
Blood pressure reduction after catheter-based renal denervation in patients with cardiovascular disease in the global symplicity registry
Felix Mahfoud,Roland E. Schmieder,Markus P. Schlaich,Krzysztof Narkiewicz,Luis M. Ruilope,Bryan Williams,Martin Fahy,Giuseppe Mancia,M Bohm +8 more
TL;DR: Patients with and without a history of stroke or myocardial infarction had similar office and ambulatory SBP reductions after catheter-based RDN, suggesting efficacy of RDN regardless of baseline cardiovascular history.
Journal ArticleDOI
New approach to measurement of blood pressure in the office
Martin G. Myers,Luis M. Ruilope +1 more
TL;DR: La medicion automatica de la presion sanguinea en consulta (MAPSC) presenta importantes ventajas sobre la medicion manual de the presion arterial en consultA (MMPAC) y adoptar el uso oficial de la MAPSC de forma rutinaria en the practica clinica es hora of adopting.
Resistant Hypertension and Renal Denervation. Considerations on the Results of the Symplicity HTN-3 Trial Hipertension arterial resistente y denervacion renal. Reflexiones tras el estudio Symplicity HTN-3
Luis M. Ruilope,Fernando Arribas +1 more
TL;DR: The recent publication of the SYMPLICITY HTN-3 trial confirmed that RDN is safe, but apparently lacks efficacy, and critics of the technique have suggested that the antihypertensive efficacy of RDN should be reconsidered in the light of its results.